ARCT (Arcturus Therapeutics Holdings) E10: $-3.74 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARCT Arcturus Therapeutics Holdings Inc ARCT
48 GF Score
Price $7.05
GF Value $2.19
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings E10?

Arcturus Therapeutics Holdings ARCT -4.86% 48 E10 is $-3.74 as of Jun. 2026. GuruFocus rates ARCT with a GF Score™ of 48/100 and a GF Value™ of $2.19 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Arcturus Therapeutics Holdings's adjusted earnings per share data for the three months ended in Jun. 2026 was $-0.840. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-3.74 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 16.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Arcturus Therapeutics Holdings was 16.70% per year. The lowest was 12.60% per year. And the median was 14.65% per year.

As of today (2026-08-10), Arcturus Therapeutics Holdings's current stock price is $7.05. Arcturus Therapeutics Holdings's E10 for the quarter that ended in Jun. 2026 was $-3.74. Arcturus Therapeutics Holdings's Shiller PE Ratio of today is .


Arcturus Therapeutics Holdings  (NAS:ARCT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Arcturus Therapeutics Holdings E10 Related Terms


Arcturus Therapeutics Holdings E10 Historical Data

* Premium members only.

The historical data trend for Arcturus Therapeutics Holdings's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcturus Therapeutics Holdings E10 Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.48 -6.61 -6.10 -4.33 -3.82

Arcturus Therapeutics Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.03 -3.92 -3.82 -3.81 -3.74

ARCT vs EQ, SMNR, TNXP: E10 Comparison

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcturus Therapeutics Holdings Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's Shiller PE Ratio falls into.


ARCT
48GF Score
Arcturus Therapeutics Holdings Inc ARCT
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcturus Therapeutics Holdings E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arcturus Therapeutics Holdings's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.84/333.9520*333.9520
=-0.840

Current CPI (Jun. 2026) = 333.9520.

Arcturus Therapeutics Holdings Quarterly Data

per share eps CPI Adj_EPS
201609 -1.960 241.428 -2.711
201612 -1.540 241.432 -2.130
201703 -0.910 243.801 -1.246
201706 -0.540 244.955 -0.736
201709 -1.510 246.819 -2.043
201712 -0.495 246.524 -0.671
201803 -0.660 249.554 -0.883
201806 -0.990 251.989 -1.312
201809 -0.420 252.439 -0.556
201812 -0.090 251.233 -0.120
201903 -0.680 254.202 -0.893
201906 -0.070 256.143 -0.091
201909 -0.560 256.759 -0.728
201912 -0.760 256.974 -0.988
202003 -0.670 258.115 -0.867
202006 -0.550 257.797 -0.712
202009 -0.920 260.280 -1.180
202012 -1.360 260.474 -1.744
202103 -2.150 264.877 -2.711
202106 -2.070 271.696 -2.544
202109 -2.050 274.310 -2.496
202112 -1.470 278.802 -1.761
202203 -1.940 287.504 -2.253
202206 -0.820 296.311 -0.924
202209 -1.330 296.808 -1.496
202212 4.430 296.797 4.985
202303 1.870 301.836 2.069
202306 -1.980 305.109 -2.167
202309 -0.610 307.789 -0.662
202312 -0.320 306.746 -0.348
202403 -1.000 312.332 -1.069
202406 -0.640 314.175 -0.680
202409 -0.260 315.301 -0.275
202412 -1.110 315.605 -1.175
202503 -0.520 319.799 -0.543
202506 -0.340 322.561 -0.352
202509 -0.490 324.800 -0.504
202512 -1.030 324.054 -1.061
202603 -0.950 330.213 -0.961
202606 -0.840 333.952 -0.840

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-3.74 mean?
Arcturus Therapeutics Holdings (ARCT) has a E10 of $-3.74 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Arcturus Therapeutics Holdings and its competitors.
Is Arcturus Therapeutics Holdings' E10 too high?
Arcturus Therapeutics Holdings' current E10 is $-3.74. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' E10 compare to EQ and SMNR?
Arcturus Therapeutics Holdings' E10 of $-3.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Arcturus Therapeutics Holdings and its competitors. Arcturus Therapeutics Holdings's current E10 is $-3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.19, compared to a current price of $7.05 — trading 221.9% above its estimated fair value. The current E10 is $-3.74. Arcturus Therapeutics Holdings' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current E10 is $-3.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $7.05 is trading 221.9% above its estimated GF Value™ of $2.19. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • E10: $-3.74
  • GF Value™: $2.19 vs. price of $7.05 (221.9% above fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
48GF Score

Get the complete analysis for ARCT

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.05
Price
$2.19
GF Value